Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Partners
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Filter
News
Articles
Podcasts
Infographics
Does pharma have the power to turn back time?
Finding a way to combat the negative effects of ageing could save healthcare systems millions. Learn whether ageing could be the next big pharma market to take the world by storm.
Read more
Does pharma have the power to turn back time?
Finding a way to combat the negative effects of ageing could save healthcare systems millions. Learn whether ageing could be the next big pharma market to take the world by storm.
Roundtable: How can pharma close the gender health gap?
Robyn Widenmaier (GSK) and Tabetha Sundin (AstraZeneca) discuss whether bids to improve gender parity could be the ticket to change in women’s health.
Get ready for Gen Z doctors
A new generation of doctors is making their way into the workforce, but is the pharmaceutical industry ready to change its tactics to engage these younger HCPs?
Has medical affairs reached 'strategic pillar' standing?
The value of medical affairs is not up for debate, but are companies allocating enough time and resources to make it the strategic function it can be?
VPAG: the UK's ticket to pharma superpower status?
A deal ends months of wrangling between the UK government and the ABPI, but what will it mean for the industry and the UK’s bid to become a life sciences superpower?
Roundtable: Was it worth the risk?
With compliance and regulatory hoops to jump through, medical affairs teams can be reluctant to try new tactics. This roundtable uncovers their relationship with risk and asks what the future holds.
Dr Peter Ahnesorg on why leaders must never stop learning
Peter Ahnesorg, Global Hematology Franchise Head, Roche, talks about his background in biochemistry, his hopes for the haematology space and his approach to leadership.
Hematology: where's it been and where's it going?
Discover the past and future of hematology. Uncover the challenges, advancements, and the industry’s commitment to patient well-being.
Loading posts...
1
2
3
…
29
Next »